NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Revolutionize Drug Discovery
Summary
NVIDIA and Eli Lilly unveil a groundbreaking $1 billion AI co-innovation lab that promises to revolutionize drug discovery by creating a continuous learning system connecting physical laboratories with computational AI for round-the-clock experimentation and pharmaceutical development.
Key Points
- NVIDIA and Eli Lilly announce a first-of-its-kind AI co-innovation lab with up to $1 billion investment over five years to revolutionize drug discovery using artificial intelligence
- The lab combines Lilly's pharmaceutical expertise with NVIDIA's AI technology, creating a continuous learning system that connects wet labs with computational dry labs for 24/7 AI-assisted experimentation
- The collaboration expands beyond drug discovery to include AI applications in clinical development, manufacturing operations, and supply chain optimization using digital twins and robotics